Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for Cue Biopharma (CUE) over the last 8 years, with Q3 2025 value amounting to 346.53%.

  • Cue Biopharma's EBITDA Margin fell 869400.0% to 346.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 530.73%, marking a year-over-year decrease of 627100.0%. This contributed to the annual value of 437.97% for FY2024, which is 4843800.0% up from last year.
  • Per Cue Biopharma's latest filing, its EBITDA Margin stood at 346.53% for Q3 2025, which was down 869400.0% from 287.14% recorded in Q2 2025.
  • In the past 5 years, Cue Biopharma's EBITDA Margin ranged from a high of 101.57% in Q4 2021 and a low of 50800.0% during Q2 2022
  • For the 5-year period, Cue Biopharma's EBITDA Margin averaged around 4982.32%, with its median value being 719.1% (2024).
  • Per our database at Business Quant, Cue Biopharma's EBITDA Margin tumbled by -504247200bps in 2022 and then skyrocketed by 498484100bps in 2023.
  • Quarter analysis of 5 years shows Cue Biopharma's EBITDA Margin stood at 101.57% in 2021, then crashed by -9416bps to 9666.23% in 2022, then soared by 92bps to 737.73% in 2023, then rose by 18bps to 602.54% in 2024, then skyrocketed by 42bps to 346.53% in 2025.
  • Its EBITDA Margin was 346.53% in Q3 2025, compared to 287.14% in Q2 2025 and 2911.4% in Q1 2025.